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ABSTRACT
Background. Near-infrared (NIR) fluorescence is a
promising novel imaging technique that can aid in intra-
operative demarcation of pancreatic cancer (PDAC) and
thus increase radical resection rates. This study investi-
gated SGM-101, a novel, fluorescent-labeled anti-
carcinoembryonic antigen (CEA) antibody. The phase 1
study aimed to assess the tolerability and feasibility of
intraoperative fluorescence tumor imaging using SGM-101
in patients undergoing a surgical exploration for PDAC.
Methods. At least 48 h before undergoing surgery for
PDAC, 12 patients were injected intravenously with 5, 7.5,
or 10 mg of SGM-101. Tolerability assessments were
performed at regular intervals after dosing. The surgical
field was imaged using the Quest NIR imaging system.
Concordance between fluorescence and tumor presence on
histopathology was studied.
Results. In this study, SGM-101 specifically accumulated
in CEA-expressing primary tumors and peritoneal and liver
metastases, allowing real-time intraoperative fluorescence
imaging. The mean tumor-to-background ratio (TBR) was
1.6 for primary tumors and 1.7 for metastatic lesions. One
false-positive lesion was detected (CEA-expressing intra-
ductal papillary mucinous neoplasm). False-negativity was
seen twice as a consequence of overlying blood or tissue
that blocked the fluorescent signal.
Conclusion. The use of a fluorescent-labeled anti-CEA
antibody was safe and feasible for the intraoperative
detection of both primary PDAC and metastases. These
results warrant further research to determine the impact of
this technique on clinical decision making and overall
survival.
Surgical resection is the only possible curative treatment
for patients with pancreatic ductal adenocarcinoma
(PDAC). Differentiation between tumoral and non-tumoral
tissue is often difficult during PDAC surgery, and this can
lead to incomplete cancer removal, exemplified by high
percentages of irradical resections.1–3 As survival time
doubles for patients with a microscopically radical resec-
tion,4 enhanced intraoperative visualization of PDAC is
crucial to increase radical resection rates and improve
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patient outcomes. Image-guided surgery using near-in-
frared (NIR) fluorescence is a novel imaging technique that
can aid in real-time demarcation of tumors during surgery.5
To detect tumors using NIR fluorescence imaging, a
fluorescent contrast agent is administered, and the distri-
bution of the agent is visualized using a dedicated imaging
system. At first, the fluorescence-imaging field focused
predominantly on indocyanine green (ICG), a nonspecific
imaging agent, because ICG is available for clinical use.
Exploiting the hypothesized passive accumulation of ICG
in tumor cells, a study in PDAC was performed.6 The
results were unfavorable because sufficient contrast
between the tumor and surrounding pancreatic tissue was
not achieved.
Currently, the fluorescence-imaging field focuses mainly
on tumor-specific agents (e.g., antibodies or ligands con-
jugated to a fluorophore) that molecularly target
biomarkers expressed by tumor cells. Recently, clinical
trials (including one randomized controlled trial) with these
tumor-specific fluorescent agents in other cancer types
have demonstrated feasibility and potential clinical benefits
of image-guided surgery.7–9 However, tumor-specific
agents for fluorescence imaging of PDAC have not been
investigated.
A number of tumor-specific imaging agent seem to have
high potential for specific fluorescence imaging of PDAC
including integrin avb6, carcinoembryonic antigen (CEA),
epithelial growth factor receptor (EGFR), and urokinase
plasminogen activator receptor (uPAR).10 As a glycoprotein
produced by gastrointestinal tissue, CEA is overexpressed in
many cancer types, including pancreatic ductal adenocarci-
noma.11,12 Antibodies directed toward CEA-overexpressing
tumors for various therapeutic applications have been suc-
cessfully tested in trials.13–15 Moreover, imaging studies
using positron emission tomography (PET) and radiola-
belled anti-CEA antibodies have demonstrated high tumor
uptake and good contrast.16,17
This study investigated the use of a novel fluorescent-
labeled (700 nm) anti-CEA antibody for clinical applica-
tion. In PDAC orthotopic mouse models using BxPC3
cells, different fluorescent-labeled anti-CEA antibodies
have allowed clear tumor delineation.18–20 Our study aimed
to assess the tolerability and feasibility of intraoperative
fluorescence tumor imaging using SGM-101 for patients
undergoing a surgical exploration for PDAC.
METHODS
Study Design
This study was an open-label, single-ascending-dose,
exploratory study of 12 patients approved by a certified
medical ethics review board (clinicaltrials.gov ID:
NCT02973672). The study primarily aimed to assess SGM-
101 with respect to tolerability and performance in the
intraoperative detection of PDAC lesions.
Due to the exploratory nature of the study, sample size was
not based on a formal calculation of statistical power. A dose-
escalating scheme with intravenous doses of 5, 7.5 and 10 mg
administered 48 or 96 h before surgery was used based on our
preclinical data.18 We included patients with elevated plasma
CEA levels ([ 3 ng/mL) who had a clinical diagnosis of
PDAC and were scheduled for surgical exploration.
The exclusion criteria ruled out pregnancy, history of
allergic reactions, impaired renal function, plasma CEA
level higher than 300 ng/mL and a diagnosis of another
malignancy within the last 5 years. Tolerability assessment
(adverse events, electrocardiogram, blood pressure, pulse,
peripheral oxygen saturation, respiratory rate, and tem-
perature), routine laboratory tests, and urine collection for
urinalysis were performed at regular intervals, starting just
before SGM-101 administration and lasting until 12 h after
dosing.
On both the day of surgery and the first postoperative
day, measurements were repeated. Follow-up visits coin-
ciding with clinical care took place on the day of discharge
and at the first outpatient clinic visit. Adverse events and
the concomitant use of other medications were recorded
throughout the study period.
All surgical procedures were open procedures, and the
surgical field was explored using standard visual and tactile
methods, complemented with ultrasound based on the sur-
geon’s preference. Subsequently, the fluorescence imaging
system was used to identify NIR-fluorescent lesions. All
lesions identified by visual/tactile methods and/or NIR flu-
orescence were resected if resection was surgically feasible
and clinically relevant. Each resected lesion was marked on a
case report form as fluorescent or non-fluorescent and as
clinically suspected of malignancy or not.
After resection, fluorescence imaging of the resected
specimen (before and after slicing) was performed in the
pathology department. The slice containing the peak fluo-
rescence signal was imaged using the Pearl imager and
corresponding software (LI-COR, Lincoln, NE, USA). The
fluorescence signal in tumor and background tissue (tumor-
to-background ratio [TBR]) was quantified using ImageJ
(version 1.49b; NIH, Bethesda, MD, USA; http://imagej.
nih.gov/ij/) on tagged image file format (TIFF) images (8
bits) subtracted from intraoperative videos. Tumor status
was correlated with intraoperative fluorescent assessment.
A tumor-positive, fluorescent lesion was regarded as a true-
positive. A tumor-negative, fluorescent lesion was regarded
as a false-positive, and a tumor-positive, non-fluorescent
lesion was regarded as a false-negative.
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In addition, immunohistochemistry (IHC) was performed
to demonstrate CEA expression. To correlate SGM-101
presence with tumor status and CEA expression on a micro-
scopic level, sections were scanned using the Odyssey imager
(LI-COR). In this report, both TBR and patient characteristics
are reported as mean ± standard deviation and range.
Investigational Product
The tumor-specific imaging agent, SGM-101 (molecular
weight, 148.6 kDa), consists of an anti-CEA chimeric
monoclonal antibody covalently bound to fluorophore BM-
104 (excitation, 686 nm; emission, 704 nm). Approximately
30–40% of the antibody is unconjugated, and the average
number of fluorophores per antibody is between 1 and 2.
In compliance with good manufacturing practice
(GMP), SGM-101 was manufactured by Novasep (Gos-
selies, Belgium). The agent was supplied by Surgimab
(Montpellier, France) as a sterile solution for injection in
amber glass vials containing 10 mg of SGM-101 in 10 mL
and stored in frozen form at - 20 C. Before SGM-101
administration, the frozen vials were thawed and diluted in
100 mL of 0.9% NaCl and infused for 30 min.
Imaging System
Imaging was performed using the Artemis and Spectrum
fluorescence imaging systems (Quest Medical Imaging,
Middenmeer, the Netherlands21). Both systems consist of
three wavelength-isolated light sources, including a
‘‘white’’ light source and two separate NIR light sources.
For this study, the Cy5,5 filter setting (fluorescent range,
680 ± 30 nm) was used. Color video and fluorescence ima-
ges were acquired simultaneously by separate sensors and
displayed in real time using custom-built optics and software,
thereby displaying color video and NIR fluorescence images
separately. A pseudo-colored (lime green) merged image of
the color video and fluorescence images also was generated.
The gain and exposure time settings were controlled using the
Quest software. An average gain setting of 25 was used, and
exposure time was varied between 60 and 120 ms according
to the clinical situation. The camera was attached to a freely
moveable arm. During surgery, the camera and moveable arm
were enclosed in a sterile shield and drape (Medical Tech-
nique Inc., Tucson, AZ, USA).
RESULTS
General
The study investigated 12 patients. Demographics and
details on surgical procedure are summarized in Table 1.
Dose Escalation
Because the increase from 5 to 7.5 mg did not cause an
increase in TBR, the interval between SGM-101 adminis-
tration and surgery was prolonged to 96 h, while the dose
remained equal at 7.5 mg for the following cohort. The
longer interval between SGM-101 administration and sur-
gery resulted in an improvement of TBR. Hence, the last
dose level was increased to 10 mg, while the longer interval
was retained. The TBR results are summarized in Fig. 1.
Safety Data
One patient (ID no. 208) experienced mild, self-limiting
abdominal discomfort and diarrhea on the day of SGM-101
administration (dose, 7.5 mg), although these symptoms
likely were not related to SGM-101. Causality could not be
excluded. In the remaining patients, adverse events related
to SGM-101 were not seen. After the surgical procedure,
four severe adverse events were noted, all related to the
surgical procedure or to disease progression.
Primary Tumor
In one patient (ID no. 206), the surgical procedure was
abandoned before the primary tumor was visualized after
detection of occult liver metastases. In the remaining 11
patients, the primary tumor was always visualized with
fluorescence imaging (TBR, 1.6 ± 0.37; range, 1.3–2.3;
Fig. 2 and Table 1). Tumor specimens were not available if
the surgical procedure was abandoned due to unre-
sectability or metastases. Consequently, ex vivo
fluorescence measurements and correlation of fluorescence
signal and histopathology were assessed in seven primary
tumors. Assessment of one slice containing peak fluores-
cence per resection specimen with the Pearl demonstrated a
mean TBR of 3.2 ± 0.79 (range, 1.7–4.1; Table 1). Six
primary tumors were confirmed as adenocarcinomas on
histopathology. The IHC for CEA showed moderate to
strong CEA overexpression (Table 1). Odyssey scans of
the fluorescence signal in the primary tumor sections
showed concordance with tumor cells on histopathology
(Fig. 2). The remaining tumor was an intraductal papillary
mucinous neoplasm (IPMN) with low-grade dysplasia.
Because this is a pre-malignant condition, the fluorescence
signal was deemed false-positive. Moderate CEA expres-
sion was present in 10–50% of IPMN lesional cells,
explaining the fluorescence.
Other Lesions
In three patients, liver and/or peritoneal metastases were
identified (with both methods) during surgery, whereas in
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only one patient (ID no. 209), a possible liver metastasis
(3 mm) was seen on cross-sectional imaging (computed
tomography [CT] scan). All metastatic lesions were fluo-
rescent (TBR, 1.7 ± 0.42; range, 1.2–2.3; Fig. 3). The IHC
for CEA showed moderate to strong CEA overexpression
(Table 1). A total of eight clinically suspect, non-fluores-
cent lesions were resected. In two patients. This non-
fluorescent tissue contained malignancy, a suspected tumor
ingrowth in the common hepatic artery (TBR, 1.3; ID no.
204), and a suspected 1-cm aorta-caval lymph node (TBR,
1.1; ID no. 207).
In frozen-section analysis, the biopsy of the ingrowth in
the common hepatic artery demonstrated adenocarcinoma
(i.e., false–negative). Frozen section analysis precluded
further ex vivo assessment of this biopsy material. The
non-fluorescent lymph node contained a metastasis and
also was considered a false-negative. Remarkably, ex vivo
imaging using the Pearl demonstrated localization of flu-
orescence, and IHC staining demonstrated CEA
expression.
DISCUSSION
We assessed the safety and feasibility of intraoperative
fluorescence imaging of PDAC using SGM-101 in 12
patients. Administration of SGM-101 doses of 5–10 mg
appeared to be safe because the occurrence of a possibly
related adverse event was limited to one subject. Moreover,
administration of SGM-101 did not cause changes in safety
measurements including vital signs, ECG, and routine
chemistry, hematology, and coagulation laboratory tests.
Intraoperative fluorescence imaging of PDAC was fea-
sible because fluorescence could be detected in primary
tumors as well as liver and peritoneal metastases. This
demonstrates that despite the suboptimal intrinsic charac-
teristics of PDAC, including poor vascularization, SGM-
101 can reach and bind the CEA-expressing tumor cells.
However, the TBRs in this study were more modest than
for other tumor types (1.6 for primary tumors and 1.7 for
metastases). This also could be explained by the
histopathology of pancreatic adenocarcinoma, with solitary
ducts of tumor cells in preexistent normal pancreatic tissue
and a remarkable desmoplastic stroma, which could make
the fluorescence pattern more sparse than with other tumor
types. Finally, SGM-101 fluoresces at about 700 nm, and
this ‘‘far red’’ part of the spectrum is associated with more
autofluorescence of the surrounding background.
Overlying tissue and blood in the surgical field likely
caused both cases of intraoperative false-negativity in this
study. The maximal depth of fluorescence signal penetra-
tion is approximately 1 cm below the tissue surface.22
Consequently, more deeply seated tumors will not be
detectable using fluorescence imaging. Moreover, absorp-
tion of the fluorescence signal by blood can have a negative
impact on the detection of the fluorescence signal.23 Thus,
it may be beneficial to combine fluorescence with other
methods, such as radionuclides or photo-acoustic imaging,
to increase detection of deeply seated or covered tumors.
For example, a study with administration of (111)In-
girentuximab-IRDye800CW has been initiated for patients
with clear cell renal cell carcinoma. An ex vivo study with
this agent has already demonstrated that uptake in tumor
tissue can be visualized using both radionuclide and fluo-
rescence imaging.24 The advantage of a radionuclide is not
only that it allows increased penetration depth, but also that
it also allows preoperative scanning.
Based on both preclinical and clinical studies, CEA was
chosen as a suitable target for fluorescence imaging of
PDAC. The current study confirmed its potential as a target
for intraoperative fluorescence imaging. Because PDAC is
characterized by several genetic mutations such as KRAS
(90%), CDK2NA (90%), TP53 (75–90%), and SMAD4/
DPDAC4 (50%),25 various other targets are expressed on
PDAC including integrin avb6, EGFR, and uPAR.10 Once
results from other clinical studies using different tumor-
specific agents become available, a cocktail of selected
agents likely will be used in a personalized manner to
increase the yield of fluorescence imaging.5 In addition, the
targeting of tumor stroma could be pursued to increase
sensitivity. Because PDAC is composed of abundant
desmoplastic stroma located at the invasive front of the
tumor, this tumor is particularly suited for stroma
targeting.26
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FIG. 1 Tumor and background fluorescence signal (in arbitrary units
[AU]) and mean tumor-to-background ratio (TBR) per dose group.
The influence of SGM-101 dose and timing on the fluorescence signal
and TBR seemed limited in this study
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By demonstrating that both primary tumors and small
metastases can be visualized using intraoperative fluores-
cence imaging, this study provided the first step toward
implementing fluorescence-guided PDAC surgery. How-
ever, larger clinical studies are needed to assess whether
this technique allows evaluation of resectability and margin
assessment (including vascular involvement) and whether
this will ultimately translate into improved overall survival.
Moreover, several challenges need to be addressed
before fluorescence imaging can be implemented in a
broader surgical practice. Funding and awareness are
required to initiate phase 3 multicenter trials. Regulatory
hurdles for approval of both imaging agents and imaging
systems need to be overcome, and standardization of
imaging systems is required to ensure accurate and repro-
ducible results.27
To the best of our knowledge, this study is the first to
describe a tumor-specific imaging agent for intraoperative
fluorescence imaging of PDAC. The use of a fluorescent-
labeled anti-CEA antibody was safe and feasible for the
detection of both primary tumors and metastases. These
results underscore the great potential of image-guided
surgery, but more prospective research is necessary to
establish the effect on clinical decision making and overall
survival.
FIG. 2 Fluorescence detection of a primary pancreatic tumor.
a Color (left column), fluorescence (middle column), and merged
(right column) images from intraoperative imaging of a pancreatic
tumor using the Quest imaging system. b Color (left column),
fluorescence (middle left column), and merged (middle right column)
images of ex vivo imaging of a slice from the same pancreatic tumor
using the Quest imaging system and to the Pearl imager (right
column). c Histopathologic evaluation and fluorescence signal in a
primary pancreatic tumor. Fluorescence microscopy (left column)
showing accumulation of SGM-101 in tumor cells. The fluorescence
pattern is consistent with carcinoembryonic antigen (CEA) expression
measured using immunohistochemistry (IHC, middle column), which
corresponds to the site containing tumor cells visible on hematoxylin
and eosin (H&E) staining (right column). Note: The acuity of the
images is suboptimal compared with the intraoperative setting
because these tagged image file format (TIFF) images (8 bits) were
subtracted from the intraoperative videos
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